Posted: 12/15/2024 11:45 am
This package marks a notable increase relative to previous years. In 2022, Dina Masi, the Chief Financial Officer, received a total compensation of $300,238. This included a salary of $253,762 and an option award of $36,905, with the rest allocated to other compensations[2]. Back in 2021, the company’s Executive Chairman and President received $257,411 as total compensation. The salary constituted $206,034, with the remaining being other forms of compensation[3].
In a parallel development, over the course of 2020, the Co-Chief Executive Officers each received total compensations of $225,955, with a consistent salary of $213,577 and minimal variations in other compensatory categories[4][5]. This increase in compensation aligns with the financial and operational growth of Integrated BioPharma as it continues to streamline its business operations in the competitive pharmaceutical industry.
At a snapshot of its current market performance, Integrated BioPharma, Inc.'s stock trades at $0.32, showing an impressive increase of approximately 24.27% recently. The stock price marked a day-high of $0.32 and a day-low of $0.2575, reflecting investor enthusiasm and heightened trading activity. The company's market capitalization stands at $9.63 million, with a price-to-earnings (PE) ratio of 16, suggesting a balanced valuation compared to its earnings[6]. This stock performance, coupled with the company's prudent compensation strategies, highlights its committed navigation through market dynamics and firm leadership efforts in enhancing shareholder value.
As Integrated BioPharma, Inc. continues to expand its footprint within the pharmaceutical marketplace, the structuring of executive compensation packages evidently plays a significant role in aligning company objectives, motivating leadership, and driving sustained corporate growth. The forthcoming earnings announcement scheduled for early 2025 is anticipated by stakeholders to shed further light on the company's financial trajectory and strategic directions[6].
---
:
1. 2024 Compensation Disclosure, U.S. Securities and Exchange Commission. [Link](https://www.sec.gov/Archives/edgar/data/1016504/000143774924032295/0001437749-24-032295-index.htm)
2. 2022 Compensation Disclosure, U.S. Securities and Exchange Commission. [Link](https://www.sec.gov/Archives/edgar/data/1016504/000143774923029180/0001437749-23-029180-index.htm)
3. 2021 Compensation Disclosure, U.S. Securities and Exchange Commission. [Link](https://www.sec.gov/Archives/edgar/data/1016504/000143774922024952/0001437749-22-024952-index.htm)
4. 2020 Compensation Disclosure (First Co-CEO), U.S. Securities and Exchange Commission. [Link](https://www.sec.gov/Archives/edgar/data/1016504/000143774921024366/0001437749-21-024366-index.htm)
5. 2020 Compensation Disclosure (Second Co-CEO), U.S. Securities and Exchange Commission. [Link](https://www.sec.gov/Archives/edgar/data/1016504/000143774920021799/0001437749-20-021799-index.htm)
6. Integrated BioPharma, Inc. Stock Data. [Link]
